MK-0646 Insulin Growth Factor 1 Receptor Antibody in Stage IIIb or IV Metastatic Non-Squamous Lung Cancer
Status:
Completed
Trial end date:
2014-07-01
Target enrollment:
Participant gender:
Summary
This study will compare the rate of chemotherapy: pemetrexed and cisplatin compared with the
combination of pemetrexed/cisplatin with MK-0646. The other purposes are to determine how
long we can control the cancer growth and toxicity and safety of the combination. Laboratory
research with the tumor tissue and blood obtained will be done to assess IGF-1R expression
and related markers and correlate with response and survival.